Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Castle Biosciences Inc CSTL

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:CSTL)

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

Business Wire April 11, 2024

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

Business Wire April 10, 2024

Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Business Wire April 10, 2024

Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

Business Wire April 4, 2024

Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire April 2, 2024

Castle Biosciences Announces Updates to its Board of Directors

Business Wire March 27, 2024

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

Business Wire March 25, 2024

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Business Wire March 22, 2024

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

Business Wire March 19, 2024

Opinion & Analysis (NDAQ:CSTL)

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue

Streetwise Reports November 13, 2019

Bullboard Posts (NDAQ:CSTL)

Study Finds DecisionDx&#xAE;-Melanoma Significantly Improves

Breaking News: $CSTL Study Finds DecisionDx&#xAE;-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I...
whytestocks - February 26, 2024